KURA on Nasdaq
Kura Oncology
American pharmaceutical preparations company based in La Jolla, founded in 2014.1
Price unavailable
Last updated Oct 18, 2026.
Overview
2014Founded1
Compare with Zentalis Pharmaceuticals, Inc., Rockwell Medical Inc. or ENANTA PHARMACEUTICALS INC, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-449.9%Operating margin4
-412.9%Net margin4
25.2%Revenue growth, 20254
-160.0%Return on equity4
0.06×Debt to equity4
-$70.7MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Collaboration revenue brought in 50% of the revenue Kura Oncology broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Collaboration revenue | $0 | $53.9M | $65.3M |
| Collaboration Revenue | $53.9M | $65.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development68¢$251.1M
- Selling, general and admin32¢$120.0M
- Income tax0¢$297.0K
Out of $67.5M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $67.5M | $53.9M | $0 |
| Cost of product sales | $57.0K | $0 | $0 |
| Research and development | $251.1M | $170.0M | $115.2M |
| Selling, general and administrative | $120.0M | $77.1M | $50.6M |
| Total operating expenses | $371.1M | $247.1M | $165.8M |
| Loss from operations | -$303.6M | -$193.2M | -$165.8M |
| Interest and other income, net | $26.8M | $22.8M | $14.7M |
| Interest expense | -$1.5M | -$1.6M | -$1.5M |
| Total other income, net | $25.3M | $21.2M | $13.2M |
| Loss before income taxes | -$278.4M | -$172.0M | -$152.6M |
| Income tax expense | $297.0K | $2.0M | $0 |
| Net Loss | -$278.7M | -$174.0M | -$152.6M |
| Net loss per share, basic | -$3.18 | -$2.02 | -$2.08 |
| Net loss per share, diluted | -$3.18 | -$2.02 | -$2.08 |
| Weighted average number of shares used in computing net loss per share, basic | 87.7M shares | 86.2M shares | 73.2M shares |
| Weighted average number of shares used in computing net loss per share, diluted | 87.7M shares | 86.2M shares | 73.2M shares |
| Unrealized gain on short-term investments | $260.0K | $2.0M | $6.8M |
| Comprehensive loss | -$278.4M | -$171.9M | -$145.9M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $149.1M | $224.5M | ||
| Short-term investments | $518.1M | $502.9M | ||
| Accounts receivable, net | $8.8M | $2.1M | ||
| Inventory | $413.0K | $0 | ||
| Prepaid expenses and other current assets | $32.2M | $15.4M | ||
| Total current assets | $708.7M | $744.8M | ||
| Property and equipment, net | $7.9M | $1.7M | ||
| Operating lease right-of-use assets | $7.3M | $5.8M | ||
| Other long-term assets | $14.5M | $7.8M | ||
| Total assets | $738.4M | $760.2M | ||
| Accounts payable | $5.0M | $1.5M | ||
| Accrued expenses and other current liabilities | $61.7M | $48.5M | ||
| Current operating lease liabilities | $1.3M | $1.9M | ||
| Current portion of long-term debt | $0 | $2.6M | ||
| Current portion of contract liabilities | $49.0M | $24.3M | ||
| Total current liabilities | $117.0M | $78.7M | ||
| Long-term debt, net of current portion | $9.7M | $6.9M | ||
| Long-term operating lease liabilities | $9.5M | $5.2M | ||
| Other long-term liabilities | $3.2M | $1.8M | ||
| Long-term contract liabilities | $424.9M | $253.9M | ||
| Total liabilities | $564.2M | $346.5M | ||
| Common stock, $0.0001 par value; 200,000 shares authorized; 87,855 and 78,229 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $9.0K | $8.0K | ||
| Additional paid-in capital | $1.3B | $1.3B | ||
| Accumulated other comprehensive income | $1.0M | $764.0K | ||
| Accumulated deficit | -$1.2B | -$895.4M | ||
| Total stockholders' equity | $174.1M | $413.6M | $397.3M | $420.3M |
| Total liabilities and stockholders' equity | $738.4M | $760.2M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 200.0M shares | 200.0M shares | ||
| Common stock, shares issued | 87.9M shares | 78.2M shares | ||
| Common stock, shares outstanding | 87.9M shares | 78.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $149.1M | $224.5M | ||
| Short-term investments | $518.1M | $502.9M | ||
| Accounts receivable, net | $8.8M | $2.1M | ||
| Inventory | $413.0K | $0 | ||
| Prepaid expenses and other current assets | $32.2M | $15.4M | ||
| Total current assets | $708.7M | $744.8M | ||
| Property and equipment, net | $7.9M | $1.7M | ||
| Operating lease right-of-use assets | $7.3M | $5.8M | ||
| Other long-term assets | $14.5M | $7.8M | ||
| Total assets | $738.4M | $760.2M | ||
| Accounts payable | $5.0M | $1.5M | ||
| Accrued expenses and other current liabilities | $61.7M | $48.5M | ||
| Current operating lease liabilities | $1.3M | $1.9M | ||
| Current portion of long-term debt | $0 | $2.6M | ||
| Current portion of contract liabilities | $49.0M | $24.3M | ||
| Total current liabilities | $117.0M | $78.7M | ||
| Long-term debt, net of current portion | $9.7M | $6.9M | ||
| Long-term operating lease liabilities | $9.5M | $5.2M | ||
| Other long-term liabilities | $3.2M | $1.8M | ||
| Long-term contract liabilities | $424.9M | $253.9M | ||
| Total liabilities | $564.2M | $346.5M | ||
| Common stock, $0.0001 par value; 200,000 shares authorized; 87,855 and 78,229 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $9.0K | $8.0K | ||
| Additional paid-in capital | $1.3B | $1.3B | ||
| Accumulated other comprehensive income | $1.0M | $764.0K | ||
| Accumulated deficit | -$1.2B | -$895.4M | ||
| Total stockholders' equity | $174.1M | $413.6M | $397.3M | $420.3M |
| Total liabilities and stockholders' equity | $738.4M | $760.2M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 200.0M shares | 200.0M shares | ||
| Common stock, shares issued | 87.9M shares | 78.2M shares | ||
| Common stock, shares outstanding | 87.9M shares | 78.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$278.7M | -$174.0M | -$152.6M |
| Share-based compensation expense | $37.1M | $33.9M | $28.1M |
| Amortization of premium and accretion of discounts on short-term investments, net | -$8.5M | -$13.1M | -$9.4M |
| Depreciation expense | $1.0M | $848.0K | $849.0K |
| Non-cash interest expense | $515.0K | $523.0K | $477.0K |
| Accounts receivable, net | -$6.7M | -$2.1M | $0 |
| Inventory | -$413.0K | $0 | $0 |
| Prepaid expenses and other current assets | -$15.9M | -$6.8M | -$2.0M |
| Accounts payable | $4.5M | -$1.6M | -$924.0K |
| Accrued expenses and other current liabilities | $12.7M | $16.8M | $11.3M |
| Operating lease right-of-use and other long-term assets | -$6.4M | $947.0K | -$685.0K |
| Other long-term liabilities | $1.0M | $758.0K | $137.0K |
| Contract liabilities | $195.7M | $278.2M | $0 |
| Net cash (used in) provided by operating activities | -$64.1M | $134.3M | -$124.8M |
| Purchases of short-term investments | -$761.6M | -$659.0M | -$409.8M |
| Maturities of short-term investments | $755.1M | $557.9M | $425.5M |
| Purchases of property and equipment | -$6.6M | -$472.0K | -$168.0K |
| Net cash (used in) provided by investing activities | -$13.1M | -$101.6M | $15.6M |
| Proceeds from issuance of stock under equity plans | $1.8M | $8.6M | $1.2M |
| Proceeds from issuances of common stock and pre-funded warrants, net of offering costs | $0 | $145.8M | $93.6M |
| Net cash provided by financing activities | $1.8M | $154.4M | $94.8M |
| Net (decrease) increase in cash and cash equivalents | -$75.4M | $187.1M | -$14.5M |
| Interest paid | $998.0K | $1.1M | $1.1M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Kura Oncology, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerTroy Edward Wilson Mar 16, 2015 to now12
- PresidentTroy Edward Wilson Mar 16, 2015 to now12
- PresidentJohn Pappajohn Apr 4, 2008 to Mar 10, 201513
- Chief financial officerJennifer Fulk Sep 10, 2026 to now14
- Chief financial officerMarc Grasso Aug 22, 2018 to Jan 28, 202215
- Chief financial officerHeidi Henson Mar 16, 2015 to Jan 26, 201816
- Chief financial officerMatthew P. Kinley Apr 4, 2008 to Mar 10, 201517
- Chief operating officerKathleen Ford Aug 13, 2019 to now18
- Chief operating officerJohn Farnam Jul 3, 2018 to Jan 24, 201919
Board members and other officers (23)
- Chief Scientific OfficerFrancis Burrows Jan 7, 2025 to now20
- Chief Medical OfficerMollie Leoni Jan 7, 2025 to now21
- Chief Commercial OfficerBrian T. Powl Aug 16, 2023 to now22
- Chief Commercial OfficerKirsten Flowers Jan 7, 2020 to Jan 31, 202323
- Acting Chief Medical OfficerBridget A. Martell Feb 12, 2020 to Dec 15, 202024
- Chief Medical OfficerStephen Dale Aug 25, 2020 to Jan 31, 202425
- Chief Medical OfficerAntonio Gualberto Mar 16, 2015 to Jul 12, 201926
- SVP, ChemistryPingda Ren Mar 16, 2015 to Jan 24, 201927
- Board memberMichael Vasconcelles Sep 17, 2024 to now28
- Board memberCarol Schafer Jun 4, 2021 to now29
- Board memberHelen Louise Collins Jul 29, 2021 to now30
- Board memberDiane L. Parks Oct 16, 2019 to now31
- Board memberMary T. Szela Nov 8, 2018 to now32
- Board memberSteven H. Stein Jan 3, 2017 to Jun 23, 202233
- Board memberTroy Edward Wilson Mar 16, 2015 to now12
- Board memberRobert Hoffman Mar 26, 2015 to Jun 23, 202134
- Board memberFaheem Hasnain Apr 27, 2015 to now35
- Board memberThomas Malley Oct 14, 2015 to now36
- Board memberJohn Pappajohn Apr 4, 2008 to Mar 10, 201513
- Board memberMatthew P. Kinley Apr 4, 2008 to Mar 10, 201517
- General counselTeresa Brophy Bair Oct 19, 2021 to now37
- General counselJames Basta Nov 5, 2019 to Jan 28, 202138
- General counselAnnette North Mar 16, 2015 to Jan 24, 201939
Former names
- ZETA ACQUISITION CORP IIIFeb 1, 2008 to Mar 10, 20153
Timeline
Filings
357 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 62 major events, 138 insider forms, 51 large holders, 1 private raises, 85 other. The latest 20:
- Sep 29, 2026144 EDGAR
- Sep 29, 2026144 EDGAR
- Sep 29, 2026144 EDGAR
- Sep 29, 20264 EDGAR
- Sep 29, 20264 EDGAR
- Sep 29, 20264 EDGAR
- Sep 29, 20264 EDGAR
- Sep 29, 20264 EDGAR
- Sep 28, 2026144 EDGAR
- Sep 28, 2026144 EDGAR
- Sep 28, 2026144 EDGAR
- Sep 28, 2026144 EDGAR
- Sep 28, 2026144 EDGAR
- Sep 28, 2026144 EDGAR
- Sep 25, 20264 EDGAR
- Sep 24, 2026144 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20263 EDGAR
- Sep 9, 20268-K EDGAR
- Sep 8, 20268-K EDGAR
The 357 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 51 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- Apr 30, 2026SCHEDULE 13G
- Mar 27, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Feb 9, 2026SCHEDULE 13G
- Nov 14, 2025SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G/A
- Aug 15, 2025SCHEDULE 13G/A
- Aug 14, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Jan 26, 2024Raised $150 million in a private offering of equity Form D: 10 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 10,509,233 | $115.3M | 0.0% | +871,702 |
| Montanova Capital, LLC | 8,575,422 | $94.1M | 2.0% | No change |
| Bvf Inc/il | 8,445,769 | $92.7M | 2.4% | No change |
| State Street Corp | 5,329,208 | $58.5M | 0.0% | +817,317 |
| Vanguard Capital Management LLC | 3,916,164 | $43.0M | 0.0% | +130,479 |
| Armistice Capital, LLC | 3,678,000 | $40.3M | 1.1% | −58,000 |
| Aqr Capital Management LLC | 3,126,727 | $34.3M | 0.0% | +1,002,247 |
| Goldman Sachs Group Inc | 2,265,171 | $24.8M | 0.0% | +831,700 |
| Geode Capital Management, LLC | 2,229,958 | $24.5M | 0.0% | +195,682 |
| Alethea Capital Management, LLC | 2,167,938 | $23.8M | 9.9% | +638,569 |
| Prosight Management, LP | 2,021,964 | $22.2M | 3.8% | −1,334,736 |
| Deep Track Capital, LP | 1,978,565 | $21.7M | 0.3% | −664,977 |
| Renaissance Technologies LLC | 1,663,765 | $18.3M | 0.0% | +81,197 |
| Arrowstreet Capital, Limited Partnership | 1,410,275 | $15.5M | 0.0% | New |
| Vanguard Portfolio Management LLC | 1,329,941 | $14.6M | 0.0% | +99,139 |
| Nan Fung Trinity (hk) Ltd | 1,174,880 | $12.9M | 1.3% | +110,000 |
| Qube Research & Technologies Ltd | 1,169,884 | $12.8M | 0.0% | −466,849 |
| Dimensional Fund Advisors LP | 1,169,189 | $12.8M | 0.0% | −256,756 |
| Bank Of America Corp /de/ | 1,160,921 | $12.7M | 0.0% | −69,210 |
| Morgan Stanley | 1,160,310 | $12.7M | 0.0% | −3,667 |
| Connor, Clark & Lunn Investment Management Ltd. | 996,114 | $10.9M | 0.0% | +195,517 |
| UBS Group AG | 964,636 | $10.6M | 0.0% | −75,597 |
| Jacobs Levy Equity Management, Inc | 948,974 | $10.4M | 0.0% | +346,743 |
| Northern Trust Corp | 831,160 | $9.1M | 0.0% | +74,887 |
| Millennium Management LLC | 711,332 | $7.8M | 0.0% | −853,811 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Dec 12, 2022 | Christopher L. Jacobs, House | Buy | $1,001 - $15,000 | −119.8% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
Links
- Websitewww.kuraoncology.com1
- X (Twitter)x.com/kuraoncology1
- WikidataQ30269121
- SEC EDGARCIK 1422143
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataKura Oncology on Wikidata
- 2SEC EDGARKura Oncology filings on SEC EDGAR
- 3SEC EDGARKura Oncology filings on SEC EDGAR
- 4SEC EDGARKura Oncology 10-K for fiscal 2025
- 5SEC EDGARKura Oncology 10-K for fiscal 2022
- 6SEC EDGARKura Oncology 10-K for fiscal 2019
- 7SEC EDGARKura Oncology 10-K for fiscal 2020
- 8SEC EDGARKura Oncology 10-K for fiscal 2021
- 9SEC EDGARKura Oncology 10-Q for fiscal 2026
- 10SEC EDGARKura Oncology 10-Q for fiscal 2026
- 11SEC EDGARKura Oncology 10-K for fiscal 2019
- 12
- 13SEC EDGARJohn Pappajohn, President
- 14
- 15SEC EDGARMarc Grasso, Chief financial officer
- 16
- 17
- 18
- 19SEC EDGARJohn Farnam, Chief operating officer
- 20
- 21SEC EDGARMollie Leoni, Chief Medical Officer
- 22
- 23
- 24
- 25SEC EDGARStephen Dale, Chief Medical Officer
- 26
- 27SEC EDGARPingda Ren, SVP, Chemistry
- 28SEC EDGARMichael Vasconcelles, Board member
- 29SEC EDGARCarol Schafer, Board member
- 30SEC EDGARHelen Louise Collins, Board member
- 31SEC EDGARDiane L. Parks, Board member
- 32SEC EDGARMary T. Szela, Board member
- 33SEC EDGARSteven H. Stein, Board member
- 34SEC EDGARRobert Hoffman, Board member
- 35SEC EDGARFaheem Hasnain, Board member
- 36SEC EDGARThomas Malley, Board member
- 37SEC EDGARTeresa Brophy Bair, General counsel
- 38SEC EDGARJames Basta, General counsel
- 39SEC EDGARAnnette North, General counsel